Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages e64-

  Stine, Jonathan G ^a   Cornella, Scott ^a   Shah, Neeral L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN;

CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMAN; MALE;

ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RIBAVIRIN;

EID: 84925229519     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206180     Document Type: Letter

References (4)

1. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
2. Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFN?/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014;73:831-7.
3. Wyles DL, et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology 2014;60:56-4.
4. Ahn J, Flamm SL. Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol 2014;10:90-100.